Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Y. J.L. Jansen*, E. A. Rozeman, R. Mason, S. M. Goldinger, M. H. Geukes Foppen, L. Hoejberg, H. Schmidt, J. V. Van Thienen, J. B.A.G. Haanen, L. Tiainen, I. M. Svane, S. Mäkelä, T. Seremet, A. Arance, R. Dummer, L. Bastholt, M. Nyakas, O. Straume, A. M. Menzies, G. V. LongV. Atkinson, C. U. Blank, B. Neyns

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Fingeraftryk

Dyk ned i forskningsemnerne om 'Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab